Examkin

Soru

Zorluk: OrtaInfectious Diseases

A 62-year-old man is evaluated in the intensive care unit for ongoing management of ventilator-associated pneumonia. He was intubated 6 days ago for severe acute respiratory distress syndrome. Three days ago, he developed a new fever, increased purulent endotracheal secretions, and worsening oxygenation. At that time, empiric intravenous vancomycin, cefepime, and ciprofloxacin were initiated. Today, his temperature is 37.2°C (99.0°F), leukocyte count has decreased from 16,000/mm³ to 9,500/mm³, and his oxygen requirements have significantly improved. Blood cultures have shown no growth. Endotracheal aspirate culture from three days ago grows Pseudomonas aeruginosa. Susceptibility testing shows the isolate is susceptible to cefepime, piperacillin-tazobactam, and ciprofloxacin. A methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction screen performed on admission was negative, and no Gram-positive organisms are seen on the respiratory culture Gram stain. Which of the following is the most appropriate next step in antibiotic management?

  1. Discontinue vancomycin and ciprofloxacin, and continue cefepime monotherapyCevap
  2. B
    Discontinue vancomycin, and continue both cefepime and ciprofloxacin
  3. C
    Continue vancomycin, cefepime, and ciprofloxacin for a full 7-day course
  4. D
    Discontinue the current regimen and switch to intravenous meropenem
  5. E
    Discontinue cefepime and ciprofloxacin, and continue vancomycin monotherapy

Cevap

Discontinue vancomycin and ciprofloxacin, and continue cefepime monotherapy
The most appropriate action is to discontinue vancomycin and ciprofloxacin, and continue cefepime monotherapy. This patient has ventilator-associated pneumonia (VAP) and is improving clinically. The respiratory culture has grown Pseudomonas aeruginosa susceptible to cefepime. The principles of antimicrobial stewardship dictate that broad-spectrum empiric therapy should be de-escalated to targeted therapy once microbiological data is available. Because there is no evidence of MRSA, vancomycin should be discontinued. Furthermore, routine double anti-pseudomonal coverage for definitive therapy is not recommended for patients who are clinically improving; a single active beta-lactam (like cefepime) is sufficient and minimizes toxicity.

Adım Adım Çözüm

1
Evaluate the clinical response to empiric therapy.
The patient's temperature, leukocyte count, and oxygenation have all improved.
Clinical stability dictates whether de-escalation of antibiotics is safe.
2
Review microbiological data to target therapy.
Cultures isolate Pseudomonas aeruginosa susceptible to cefepime, with no evidence of MRSA.
Empiric broad-spectrum therapy must be narrowed to target the specific pathogen causing the infection.
3
Determine the optimal definitive antibiotic regimen.
Discontinue vancomycin (no MRSA) and ciprofloxacin (double coverage not needed), leaving cefepime monotherapy.
Guidelines recommend monotherapy for definitive treatment of susceptible P. aeruginosa in patients who are not in septic shock or at high risk for mortality.

Anahtar Kavram

De-escalation of empiric antimicrobial therapy in ventilator-associated pneumonia involves transitioning to targeted monotherapy based on culture susceptibilities and discontinuing unneeded empiric agents like MRSA coverage.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru